Nyxoah, S.A. (NYXH) - מכפיל מחיר להכנסות עתידי

Nyxoah S.A. generates revenue from the sale of implants for patients with apnea who cannot tolerate masks. The projected price-to-sales ratio reflects the dynamics of this demand, with this metric standing at 2.80. Growth is supported by the authority of Genio systems and patent protection for unique nerve stimulators, which create significant barriers to entry for competitors in the neurostimulation segment.
Nyxoah - פילוחים אנליטיים ומדדי מפתח (NYXH)

The forward P/S reflects the ratio of the current market value of Nyxoah S.A. (NYXH) to expected annual sales, allowing for an assessment of the extent to which future growth is priced in. By analyzing the projected P/S value, an investor can determine whether the high valuation is justified by the expansion rates of implantable neurostimulators for the treatment of apnea purchased by clinics and insurance funds.